The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
Open accessAbstract
Despite promising preclinical studies with the cyclin-dependent kinase inhibitor flavopiridol in chronic lymphocytic leukemia (CLL) and other diseases, previous clinical trials with this agent have been disappointing. The discovery of differential protein binding of flavopiridol in human and bovine serum contributed to an effective pharmacokinetic-derived schedule of administration of this agent. On the basis of pharmacokinetic modeling using our in vitro results and data from a previous trial, we initiated a phase 1 study using a 30-minute loading dose followed by 4 hours of infusion administered weekly for 4 of 6 weeks in patients with refractory CLL. A group of 42 patients were enrolled on 3 cohorts (cohort 1, 30 mg/m2 loading dose followed by 30 mg/m2 4-hour infusion; cohort 2, 40 mg/m2 loading dose followed by 40 mg/m2 4-hour infusion; and cohort 3, cohort 1 dose for treatments 1 to 4, then a 30 mg/m2 loading dose followed by a 50 mg/m2 4-hour infusion). The dose-limiting toxicity using this novel schedule was hyperacute tumor lysis syndrome. Aggressive prophylaxis and exclusion of patients with leukocyte counts greater than 200 × 109/L have made this drug safe to administer at the cohort 3 dose. Of the 42 patients treated, 19 (45%) achieved a partial response with a median response duration that exceeds 12 months. Responses were noted in patients with genetically high-risk disease, including 5 (42%) of 12 patients with del(17p13.1) and 13 (72%) of 18 patients with del(11q22.3). Flavopiridol administered using this novel schedule has significant clinical activity in refractory CLL. Patients with bulky disease and high-risk genetic features have achieved durable responses, thereby justifying further study of flavopiridol in CLL and other diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B., Bennett, J., Grever, M., Kay, N., Keating, M., O'Brien, S., & Rai, K. (1996) · Blood · doi:10.1182/blood.v87.12.4990.bloodjournal87124990 · Cited by 1,819
Self-citationKeating, M. J., Flinn, I., Jain, V., Binet, J.-L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B., et al. (2002) · Blood · doi:10.1182/blood.v99.10.3554 · Cited by 948
Self-citationDohner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J., Stilgenbauer, S., et al. (1995) · Blood · doi:10.1182/blood.v85.6.1580.bloodjournal8561580 · Cited by 732
Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo
Chao, S.-H., & Price, D. H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102306200 · Cited by 621
Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P., & Fenaux, P. (1994) · Blood · doi:10.1182/blood.v84.9.3148.3148 · Cited by 591
Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication
Chao, S.-H., Fujinaga, K., Marion, J. E., Taube, R., Sausville, E. A., Senderowicz, A. M., Peterlin, B. M., & Price, D. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000446200 · Cited by 455
Senderowicz, A. M., Headlee, D., Stinson, S. F., Lush, R. M., Kalil, N., Villalba, L., Hill, K., Steinberg, S. M., Figg, W. D., Tompkins, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2986 · Cited by 403
Lozanski, G., Heerema, N. A., Flinn, I. W., Smith, L., Harbison, J., Webb, J., Moran, M., Lucas, M., Lin, T., Hackbarth, M. L., et al. (2004) · Blood · doi:10.1182/blood-2003-10-3729 · Cited by 398
Self-citationByrd, J. C., Shinn, C., Waselenko, J. K., Fuchs, E. J., Lehman, T. A., Nguyen, P. L., Flinn, I. W., Diehl, L. F., Sausville, E., & Grever, M. R. (1998) · Blood · doi:10.1182/blood.v92.10.3804 · Cited by 283
Self-citationKouroukis, C. T., Belch, A., Crump, M., Eisenhauer, E., Gascoyne, R. D., Meyer, R., Lohmann, R., Lopez, P., Powers, J., Turner, R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.057 · Cited by 277
Cited by
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Cell cycle kinases as therapeutic targets for cancer
Lapenna, S., & Giordano, A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2907 · Cited by 905
CDC25 phosphatases in cancer cells: key players? Good targets?
Boutros, R., Lobjois, V., & Ducommun, B. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2169 · Cited by 714
Chemotherapeutic Drugs Inhibit Ribosome Biogenesis at Various Levels
Burger, K., Mühl, B., Harasim, T., Rohrmoser, M., Malamoussi, A., Orban, M., Kellner, M., Gruber-Eber, A., Kremmer, E., Hölzel, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.074211 · Cited by 458
Metadata
- Authors
- Byrd, J. C., Lin, T. S., Dalton, J. T., Wu, D., Phelps, M. A., Fischer, B., Moran, M., Blum, K. A., Rovin, B., Brooker-McEldowney, M., Broering, S., Schaaf, L. J., Johnson, A. J., Lucas, D. M., Heerema, N. A., Lozanski, G., Young, D. C., Suarez, J.-R., Colevas, A. D., & Grever, M. R.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2006-09-26
- Volume
- 109
- Issue
- 2
- Pages
- 399-404
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2017898416
- Cited by
- 390
- References
- 35
- FWCI
- 19.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. https://app.cochat.ai/papers/10.1182/blood-2006-05-020735
- The paper
- Byrd, J. C., Lin, T. S., Dalton, J. T., Wu, D., Phelps, M. A., Fischer, B., Moran, M., Blum, K. A., Rovin, B., Brooker-McEldowney, M., Broering, S., Schaaf, L. J., Johnson, A. J., Lucas, D. M., Heerema, N. A., Lozanski, G., Young, D. C., Suarez, J.-R., Colevas, A. D., & Grever, M. R. (2007). Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood. https://doi.org/10.1182/blood-2006-05-020735
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.